WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

J ANTIINFECTIVES FOR SYSTEMIC USE

Antiinfectives are also classified in the following groups:
A01AB Antiinfectives and antiseptics for local oral treatment
A02BD Combinations for eradication of Helicobacter pylori
A07A Intestinal antiinfectives
D01 Antifungals for dermatological use
D06 Antibiotics and chemotherapeutics for dermatological use
D07C Corticosteroids, combinations with antibiotics
D09AA Ointment dressings with antiinfectives
D10AF Antiinfectives for treatment of acne
G01 Gynecological antiinfectives and antiseptics
P Antiparasitic products, insecticides and repellents
R02AB Antibiotics
S01/
S02/
S03 Eye and ear preparations with antiinfectives
Even systemically administered antibacterials and antimycotics may be classified in other groups if their target is exclusively local, e.g. the skin - D01 - Antifungals for dermatological use.
Inhaled antiinfectives are classified in J.

The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity. However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly. The DDDs assigned are based on daily treatment. The duration of the treatment periods is not taken into consideration. For antiinfectives given in a high initially starting dose followed by a lower daily "maintenance" dose, the DDDs are based on the "maintenance" dose if the total duration of the treat-ment course is more than one week. If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).


J02 ANTIMYCOTICS FOR SYSTEMIC USE
J02A ANTIMYCOTICS FOR SYSTEMIC USE

This group does not include antimycotics specifically for dermatological use even if they are administered systemically (see D01B).
Antimycotics - see also:
A01AB Antiinfectives and antiseptics for local oral treatment
A07A Intestinal antiinfectives
D01 Antifungals for dermatological use
G01 Gynecological antiinfectives and antiseptics
Fumagillin used in the treatment of intestinal microsporidiosis is classified in P01AX.


J02AA Antibiotics

Lipid formulations (e.g. liposomal, lipid complex) of amphotericin B have been assigned a separate, higher DDD from the conventional formulations due to a considerably higher dosage.

J02AB Imidazole derivatives

Pharmaceutical formulations of ketoconazole solely indicated for the treatment of Cushings syndrome are classified in H02CA - Anticorticosteroids.

J02AC Triazole and tetrazole derivatives

All oral and parenteral formulations of fluconazole are classified here. Fosfluconazole (prodrug of fluconazole) is classified at the same 5th level as fluconazole.
Vaginal formulations of triazole derivatives, see G01AG.

The oral DDD for posaconazole is based on the recommended dose for gastro-resistant tablets.

J02AX Other antimycotics for systemic use

Last updated: 2024-01-26